Kymera Therapeutics Inc

2026-09-02 19:46; UTC

Shares rise as JPMorgan raises price target to $140.00.

2026-08-28 20:01; UTC

Kymera Therapeutics Inc shares are lower today, continuing a decline since Thursday. Trading volume is unusually high amid rising U.S. Treasury yields.

2026-08-27 20:02; UTC

Kymera Therapeutics Inc shares are lower today, diverging from recent gains amid high trading volume and broader market resilience following a drop in jobless claims.

2026-08-25 20:07; UTC

Kymera Therapeutics shares are higher today, supported by declining oil prices and lower Treasury yields, enhancing overall investor sentiment toward equities.

2026-08-21 19:26; UTC

Kymera Therapeutics Inc shares are lower during Friday's session despite earlier gains. Analysts maintain a consensus "Moderate Buy" rating with a target of $125.65.

2026-08-20 22:01; UTC

Kymera Therapeutics Inc. shares are higher in after-market trading, supported by a broader upward trend in biotechnology stocks. The price remains above its 20-day moving average.

2026-08-19 20:02; UTC

Kymera Therapeutics is rising amid gains in the ARK Genomic Revolution ETF, which increased significantly. The stock is also experiencing high market volume today.

2026-08-18 19:26; UTC

Kymera Therapeutics Inc shares are higher today, recovering from an earlier decline. No specific news was identified to explain the movement.

2026-08-17 19:54; UTC

Kymera Therapeutics Inc shares are trading higher today amid increased volume, maintaining a positive trend since Friday's close despite earlier intraday fluctuations.

2026-08-14 20:06; UTC

Kymera Therapeutics Inc shares are higher today, recovering from an earlier pullback amid a mixed market backdrop following a decline in U.S. retail sales.

2026-08-12 20:01; UTC

Kymera Therapeutics Inc shares are trading higher amid increased activity and unusually high market volume, with no specific news identified to explain the movement.

2026-08-06 19:56; UTC

Kymera Therapeutics Inc shares are lower today, trading near the lower end of their one-month range amid broader market dynamics and inflationary concerns.

2026-08-05 20:02; UTC

Kymera Therapeutics reported a narrower net loss of $61.21 million for Q2 2026, driven by increased collaboration revenue and a price target raise from Stifel to $132.

2026-08-04 20:04; UTC

Kymera Therapeutics Inc is rising in Tuesday's session, reflecting bullish sentiment in the biotechnology sector amid a broader market uptrend.

2026-08-03 19:46; UTC

Kymera Therapeutics Inc shares are lower amid volatility, following Dimensional Fund Advisors LP's 5% stake reduction and broader market trends in biotechnology.

2026-07-31 20:06; UTC

Kymera shares lower amid SPDR S&P Biotech ETF decline.

2026-07-30 19:39; UTC

Kymera Therapeutics Inc shares are higher during Thursday's session, with no specific news identified to explain the price action amid broader market trends.

2026-07-29 19:32; UTC

Kymera Therapeutics shares are higher as the Federal Reserve maintains rates at 3.50%–3.75%. Investors monitor inflation trends and their impact on future policy.

2026-07-28 17:42; UTC

Shares lower despite Guggenheim's price target increase to $135.

2026-07-27 21:03; UTC

Kymera Therapeutics shares are lower in after-market hours following the appointment of Terence Rooney, MD, as Chief Medical Officer, succeeding Jared Gollob, MD.

2026-07-24 18:46; UTC

Kymera Therapeutics Inc. shares are roughly flat as trading fluctuates within a narrow range, reflecting routine activity without specific news.

2026-07-21 19:16; UTC

Kymera Therapeutics Inc is trading higher, supported by broader market strength and optimism in AI stocks, despite a pullback earlier in the session.

2026-07-20 22:16; UTC

Kymera Therapeutics Inc shares are lower in after-market hours. Broader market sentiment is influenced by rising Treasury yields amid interest rate and geopolitical concerns.